Mode
Text Size
Log in / Sign up

Review of arginine and levodopa stimulation testing reports hematuria in pediatric patientsRed urine after a growth test? Here is what you need to know

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note hematuria risk with arginine/levodopa testing; counsel patients and monitor closely.

This source is a case report and literature review focusing on adverse events associated with combined arginine and levodopa growth hormone stimulation testing in pediatric patients. The authors analyze data from 15 patients, comprising one primary case report and nine case reports drawn from the existing literature. The review specifically addresses the occurrence of hematuria as a primary outcome of interest during these diagnostic procedures.

The synthesized findings indicate that hematuria onset typically occurs 1 to 3 days post-administration of the test agents. In the primary case report, resolution was observed after 8 days, while the literature review cases showed resolution in approximately one week. The majority of patients were male, and most individuals presented with a change in urine color as the sole clinical manifestation. Gross hematuria with blood clots was identified as the specific adverse event profile.

The authors hypothesize that the mechanism may involve drug-induced alterations in the permeability of the glomerular filtration membrane or a triggered immune response. However, the review notes that the exact pathophysiology remains uncertain. A critical limitation is that the setting for these events was not reported, and the sample size is derived from small case series rather than a controlled trial. Consequently, the evidence is observational and does not establish definitive causality.

Given the potential for significant adverse events, the practice relevance is that clinicians must inform patients and families of this risk prior to initiating the test. Close monitoring for possible onset of hematuria post-testing is recommended to ensure patient safety and appropriate management of the condition.

The Red Urine Surprise

Imagine a parent rushing to the doctor because their child has stopped growing. The doctor orders a special test to check for growth hormone deficiency. The child drinks a sugary drink with arginine and levodopa. A few hours later, the parent sees bright red blood in the toilet. Panic sets in. Is it a kidney failure? Is it poison?

This is exactly what happened to an 11-year-old boy. He felt pain when he peed. He had large clots of blood. The doctors were worried. But after checking everything else, they found the cause. It was the test itself.

Short stature affects many children. Doctors often need to measure growth hormone levels. This is done with a stimulation test. It is safe and standard. But this new information changes how we talk about it.

We used to think this test was risk-free. Now we know it can cause red urine. This happens because the medicine changes how the kidney filters blood. It is a rare event, but it is real. Parents need to know this before the test starts.

The Old Way vs. The New Way

Before now, doctors did not warn families about red urine. If it happened, families thought the worst. They feared kidney damage. This caused unnecessary stress for everyone.

But here is the twist. The red urine is not a sign of permanent harm. It is a temporary reaction. The old way was to ignore it until it got worse. The new way is to warn parents first. This reduces fear and helps families understand what they are seeing.

Think of your kidneys like a coffee filter. They let clean water pass through but keep dirt and big particles back. The growth hormone test changes the filter slightly.

It makes the filter holes open a bit too wide. Small bits of blood slip through. This turns the urine red. It is like a dam letting a little water leak during a storm. The storm passes, and the dam seals itself again.

The body usually fixes this on its own. The kidneys heal quickly. The red color fades. No special surgery is needed.

Doctors looked at one boy and many others. They found 9 other reports in medical books. These reports covered 15 patients total. Most were boys. They were different ages.

The test involved drinking a mix of arginine and levodopa. Doctors watched the patients for several days. They checked the urine color and looked for pain. They also tested kidney function to be sure.

The boy's urine turned red seven hours after the test. He had clots and pain. Doctors treated him with fluids and medicine to change urine pH. He felt better in eight days.

The other 15 patients had similar stories. Most just saw red urine without pain. The red color showed up one to three days after the test. It usually disappeared in about a week.

But there is a catch. This reaction is rare. It does not happen to everyone. But it can happen to anyone who takes the medicine.

Doctors say this is a known but rare reaction. It is not a sign of kidney failure. The kidneys work fine after the red urine stops. The main lesson is communication.

Doctors must tell families about this risk before the test. This helps families stay calm if red urine appears. It also helps doctors watch for it early.

If your child needs this test, talk to the doctor first. Ask if they will warn you about red urine. Drink plenty of water before and after the test. This helps flush the system.

If you see red urine, do not panic. It is likely just the test working in an unusual way. Call the doctor to confirm it is safe. They will tell you to keep drinking water and rest.

This is based on a small number of cases. We do not know exactly why boys get it more often. We also do not know if other medicines cause this. More research is needed to understand the full picture.

Doctors will keep watching for this reaction. They may change how they explain risks to families. Future tests might look for ways to prevent this red urine. Until then, awareness is the best tool we have.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BackgroundArginine growth hormone (GH) testing is a commonly used and generally safe pediatric procedure for assessing GH deficiency. The occurrence of gross hematuria following this testing is a rare adverse drug reaction that had not been previously encountered at our institution, raising significant concerns among both patients and clinicians.Case presentationAn 11-year-and-3-month-old boy presented with short stature. Approximately 7 h after undergoing a combined arginine and levodopa GH stimulation testing, he developed painful gross hematuria accompanied by blood clots. A subsequent comprehensive clinical evaluation ruled out other potential etiologies, leading to the diagnosis of drug-induced hematuria. The patient was treated with urine alkalinization, and the gross hematuria substantially resolved within 8 days. Furthermore, a review of the literature identified 9 case reports involving 15 patients who developed hematuria following arginine GH stimulation testing. The majority of these patients were male, with a broad age distribution. Most individuals presented solely with a change in urine color; hematuria typically manifested within 1–3 days post-administration and resolved spontaneously within approximately 1 week. Standard management strategies primarily include urine alkalinization and fluid supplementation. Current studies hypothesize that the underlying mechanism may involve drug-induced alterations in the permeability of the glomerular filtration membrane or a triggered immune response.ConclusionsHematuria induced by GH stimulation testing is a rare but noteworthy adverse drug reaction. Therefore, prior to initiating the test, clinicians must thoroughly inform patients and their families of this potential risk to alleviate unnecessary anxiety, and closely monitor for the possible onset of hematuria post-testing.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.